Product
Tilvestamab
1 clinical trial
1 indication
Indication
Ovarian CancerClinical trial
Phase 1b, Multicentre, Multiple Ascending Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) PatientsStatus: Terminated, Estimated PCD: 2022-06-27